

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: DNA Polymerase Technology, Inc. 11 Princeton Avenue University City, MO 63130 REPORT NUMBER(S) 13-01	2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352
---	--

3. DOCKET NUMBER(S) 030-36107	4. LICENSE NUMBER(S) 24-32214-01	5. DATE(S) OF INSPECTION January 17, 2013
---	--	---

LICENSEE:
 The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

1. Based on the inspection findings, no violations were identified.

2. Previous violation(s) closed.



3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

_____ Non-cited violation(s) were discussed involving the following requirement(s):

4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
 (Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		1/17/13
BRANCH CHIEF	Tamara E. Bloomer		1/28/13

Docket File Information
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: DNA Polymerase Technology, Inc. 11 Princeton Avenue University City, MO 63130 REPORT NUMBER(S) 13-01	2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352
--	---

3. DOCKET NUMBER(S) 030-36107	4. LICENSE NUMBER(S) 24-32214-01	5. DATE(S) OF INSPECTION January 17, 2013
--------------------------------------	---	--

6. INSPECTION PROCEDURES USED 87126	7. INSPECTION FOCUS AREAS 03.01-03.07
--	--

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 03620	2. PRIORITY 5	3. LICENSEE CONTACT John Hartman, Manager	4. TELEPHONE NUMBER (314) 707-4919
---------------------------------	----------------------	--	---

Main Office Inspection Next Inspection Date: 01/17/2018

Field Office Inspection 1508 S. Grand Boulevard, St. Louis, MO

Temporary Job Site Inspection

PROGRAM SCOPE

The licensee is authorized to use phosphorus-32, phosphorus-33, and sulfur-35, for research and development as defined by Section 30.4 of 10 CFR Part 30, for in-vitro laboratory studies. The licensee has only used P-32 for research projects. At the time of the inspection, the licensee had 3 individuals authorized to use licensed material, but there had been only one research project conducted during May 2012 and involved one authorized user using 250 microcuries of P-32. The licensee's current isotope inventory indicated no licensed material was possessed by the licensee. Security of the lab was controlled by a locked entrance door and use of a call box for entry into the premises.

Performance Observations

During the inspection, the licensee's authorized user and laboratory manager demonstrated/discussed: (1) survey meter use and calibrations; (2) package ordering, receiving, and check-in procedures; (3) area and contamination surveys; (4) dosimetry (none used); (5) waste handling, storage, sewer, and decay-in storage disposal procedures; (6) unsealed isotope inventory control; (7) safe use; (8) postings and labeling; and (9) 10 CFR 30.36(d)(3) notification.

The inspector performed independent and confirmatory radiation measurements, which survey results did not indicate any contamination issues or elevated readings.